Ambutonium

Ambutonium

SCHEMBL249674

CC[N+](C)(C)CCC(C(N)=O)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Ambutonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 11/20 0.65
CHRM2 known ✓ P08172 8/20 0.65
CHRM1 known ✓ P11229 4/20 0.65
OPRM1 known ✓ P35372 2/20 0.48
CHRM4 known ✓ P08173 3/20 0.42
CHRM5 known ✓ P08912 2/20 0.39
KCNH2 Q12809 2/20 0.65
LMNA P02545 1/20 0.65
CYP2D6 P10635 1/20 0.65
KDM4E B2RXH2 1/20 0.63
CTDSP1 Q9GZU7 1/20 0.63
DRD3 P35462 2/20 0.48
DRD2 P14416 1/20 0.48
SCN1A P35498 2/20 0.46
SCN2A Q99250 2/20 0.46
SCN3A Q9NY46 2/20 0.46
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
DRD4 P21917 1/20 0.41
SLC22A2 O15244 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ambutonium SCHEMBL11946672 0.98 CHRM3 (0.67) CHRM3CHRM2CHRM1KCNH2LMNA
Isopropamide SCHEMBL100256 0.79 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2LMNA
SCHEMBL9295790 0.79 CHRM3 (0.59) CHRM3CHRM2CHRM1KCNH2LMNA
Isopropamide SCHEMBL3082703 0.78 CHRM3 (0.97) CHRM3CHRM2CHRM1KCNH2LMNA
Isopropamide SCHEMBL100255 0.78 KDM4E (1.00) CHRM3CHRM2CHRM1KCNH2LMNA
Isopropamide SCHEMBL14672609 0.77 CHRM3 (0.94) CHRM3CHRM2CHRM1KCNH2LMNA
SCHEMBL2984162 0.76 CHRM3 (0.56) CHRM3CHRM2CHRM1KCNH2LMNA
Isopropamide SCHEMBL7796559 0.75 CHRM3 (0.85) CHRM3CHRM2CHRM1KCNH2LMNA
SCHEMBL4030430 0.75 MAPT (0.55) CHRM3CHRM2CHRM1KCNH2LMNA
Hydrochloric Acid SCHEMBL30448099 0.74 CHRM3 (0.55) CHRM3CHRM2CHRM1KCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101326275-A Multifunctional ionic liquid composition UNIV ALABAMA (US) 2008-12-17 CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-5008111-A Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration SCHERING CORPORATION (US) 1991-04-16 US claimed
US-4824676-A ANTICHOLINERGIC AGENT TO SUPPRESS PERSPIRATION SCHERING CORPORATION (US) 1989-04-25 US claimed
US-20260133211-A1 REAGENT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME, AND BLOOD COAGULATION TIME REGULATOR FOR LUPUS ANTICOAGULANT-POSITIVE BLOOD SPECIMEN OR HEPARIN-CONTAINING BLOOD SPECIMEN SEKISUI MEDICAL CO., LTD. (JP) 2026-05-14 US disclosed
US-12571021-B2 Methods for quantifying starch and cellulose in corn samples EDENIQ, INC. (US) 2026-03-10 US disclosed
EP-4603841-A1 REAGENT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME, AND BLOOD COAGULATION TIME REGULATOR FOR LUPUS ANTICOAGULANT-POSITIVE BLOOD SPECIMEN OR HEPARIN-CONTAINING BLOOD SPECIMEN Sekisui Medical Co., Ltd. (JP) 2025-08-20 EP disclosed
WO-2025135129-A1 AGENT FOR IMPROVING AGGLUTINATION REACTION, METHOD FOR IMPROVING TARGET ANTIGEN MEASUREMENT METHOD, AND REAGENT FOR MEASURING HUMAN BRAIN NATRIURETIC PEPTIDE デンカ株式会社 2025-06-26 WO disclosed
CN-120019282-A Reagent for measuring activated partial thromboplastin time and clotting time regulator for lupus anticoagulant positive blood sample or heparin-containing blood sample 积水医疗株式会社 2025-05-16 CN disclosed
US-20240360491-A1 METHODS FOR QUANTIFYING STARCH AND CELLULOSE IN CORN SAMPLES EDENIQ, INC. (US) 2024-10-31 US disclosed
US-12054767-B2 Methods for quantifying starch cellulose in corn samples EDENIQ, INC. (US) 2024-08-06 US disclosed
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2024-03-07 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN disclosed
CN-1218692-A Novel Anti-spasmodic composition and process for manufacture thereof PANACEA BIOTEC LTD (IN) 1999-06-09 CN disclosed
EP-0198034-A1 PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS. KEY PHARMA (US) 1986-10-22 EP disclosed
WO-1986002272-A1 PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS KEY PHARMACEUTICALS, INC. (US) 1986-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 CHRM3 2637/4885CHRM2 2534/4885CHRM1 4149/4885
US-12571021-B2 Methods for quantifying starch and cellulose in corn samples TREH, TALDO1, CEL CHRM3 3813/4885CHRM2 2704/4885CHRM1 2157/4885
US-20260133211-A1 REAGENT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME, AND BLOOD COAGULATION TIME REGULATOR FOR LUPUS ANTICOAGULANT-POSITIVE BLOOD SPECIMEN OR HEPARIN-CONTAINING BLOOD SPECIMEN TFPI, SSB, F2 CHRM3 4331/4885CHRM2 4150/4885CHRM1 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.